Evidence map›Paper›PMID 41681875›Full record

ArticleCancers2026

High Frequency Loss of 17q11.2 and Downregulation of the Cancer Metastasis Suppression microRNA miR-193a-3p in Prostate Cancer Bone Metastasis.

Elzbieta Stankiewicz, Sarah C McCarley, Xueying Mao, Sakunthala Kudahetti, Tim Oliver, Jonathan Shamash, Trevor Graham, Daniel M Berney, Yong-Jie Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elzbieta StankiewiczBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0003-0812-4086
Sarah C McCarleyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Xueying MaoBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Sakunthala KudahettiBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Tim OliverBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Jonathan ShamashBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Trevor GrahamBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Daniel M BerneyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Yong-Jie LuBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0001-6174-6621

Funding

Cancer Research UK C16420/A18066Orchid N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

17q11.2 lossbone metastasiscell invasioncyclin D1genome-wide copy number change profilemiR-193a-3pprostate canceruPA

Identifiers

PMID41681875
PMCPMC12896823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.